Serclutamab talirine - AbbVie
Alternative Names: ABBV-321Latest Information Update: 28 May 2024
At a glance
- Originator AbbVie
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma
- No development reported Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Australia (IV, Infusion)
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Israel (IV, Infusion)
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV, Infusion)